The present invention relates to the use of a novel class of cancer stem cellpathway (CSCP) inhibitors； to methods ofusing such compounds to treat refractory, recurrent, or metastatic cancers； tomethods of selective killing cancer cells by using suchcompounds with specific administration regimen； to methods of targeting cancerstem cells by inhibiting Stat3 pathway； to methodsof using novel compounds in the treatment of conditions or disorders in amammal related to aberrant Stat3 pathway activity； and toprocesses for preparing such compounds and intermediates thereof, and to thepharmaceutical composition of relevant compounds,and to the specific methods of administration of these compounds.
